テロメラーゼ逆転写酵素とは? わかりやすく解説

Weblio 辞書 > 辞書・百科事典 > 百科事典 > テロメラーゼ逆転写酵素の意味・解説 

テロメラーゼ逆転写酵素

出典: フリー百科事典『ウィキペディア(Wikipedia)』 (2023/08/04 05:46 UTC 版)

テロメラーゼ逆転写酵素(テロメラーゼぎゃくてんしゃこうそ、: telomerase reverse transcriptase、略称: TERT、特にヒトのものはhTERTと略される)は、テロメラーゼの触媒サブユニットであり、テロメラーゼRNA構成要素(TERC)とともにテロメラーゼ複合体の重要なユニットを構成する[5][6]


  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000164362 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000021611 - Ensembl, May 2017
  3. ^ Human PubMed Reference:
  4. ^ Mouse PubMed Reference:
  5. ^ “Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT”. Nature Genetics 17 (4): 498–502. (December 1997). doi:10.1038/ng1297-498. PMID 9398860. 
  6. ^ “The significance of human telomerase reverse transcriptase (hTERT) in cancer”. European Journal of Surgical Oncology 27 (8): 754–60. (December 2001). doi:10.1053/ejso.2001.1151. PMID 11735173. 
  7. ^ “Generation of telomere-length heterogeneity in Saccharomyces cerevisiae”. Proceedings of the National Academy of Sciences of the United States of America 85 (2): 534–8. (January 1988). Bibcode1988PNAS...85..534S. doi:10.1073/pnas.85.2.534. PMC 279585. PMID 3277178. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC279585/. 
  8. ^ “Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT)”. Gene 269 (1-2): 1–12. (May 2001). doi:10.1016/S0378-1119(01)00440-1. PMID 11376932. 
  9. ^ a b “Deletion of the telomerase reverse transcriptase gene and haploinsufficiency of telomere maintenance in Cri du chat syndrome”. American Journal of Human Genetics 72 (4): 940–8. (April 2003). doi:10.1086/374565. PMC 1180356. PMID 12629597. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1180356/. 
  10. ^ “Cri du Chat syndrome”. Orphanet Journal of Rare Diseases 1: 33. (September 2006). doi:10.1186/1750-1172-1-33. PMC 1574300. PMID 16953888. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574300/. 
  11. ^ a b Entrez Gene: TERT telomerase reverse transcriptase”. 2020年5月30日閲覧。
  12. ^ a b “The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter”. Human Molecular Genetics 8 (1): 137–42. (January 1999). doi:10.1093/hmg/8.1.137. PMID 9887342. 
  13. ^ “Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization”. Neoplasia 2 (3): 197–201. (2000). doi:10.1038/sj.neo.7900092. PMC 1507564. PMID 10935505. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1507564/. 
  14. ^ a b c d e “Telomerase regulation at the crossroads of cell fate”. Cytogenetic and Genome Research 122 (3-4): 263–72. (2008). doi:10.1159/000167812. PMID 19188695. 
  15. ^ a b Kyo S, Takakura M, Fujiwara T, Inoue M (August 2008). “Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers”. Cancer Science 99 (8): 1528–38. doi:10.1111/j.1349-7006.2008.00878.x. hdl:2297/45975. PMID 18754863. https://doi.org/10.1111/j.1349-7006.2008.00878.x. 
  16. ^ a b c d Marion RM, Strati K, Li H, Tejera A, Schoeftner S, Ortega S, Serrano M, Blasco MA (February 2009). “Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells”. Cell Stem Cell 4 (2): 141–54. doi:10.1016/j.stem.2008.12.010. PMID 19200803. 
  17. ^ a b Walne AJ, Dokal I (April 2009). "Advances in the understanding of dyskeratosis congenita". British Journal of Haematology. 145 (2): 164–72. doi:10.1111/j.1365-2141.2009.07598.x. PMC 2882229. PMID 19208095
  18. ^ a b c Flores I, Benetti R, Blasco MA (June 2006). "Telomerase regulation and stem cell behaviour". Current Opinion in Cell Biology. 18 (3): 254–60. doi:10.1016/j.ceb.2006.03.003. PMID 16617011
  19. ^ Calado R, Young N (2012). "Telomeres in disease". F1000 Medicine Reports. 4: 8. doi:10.3410/M4-8. PMC 3318193. PMID 22500192
  20. ^ a b Flores I, Blasco MA (September 2010). "The role of telomeres and telomerase in stem cell aging". FEBS Letters. 584 (17): 3826–30. doi:10.1016/j.febslet.2010.07.042. PMID 20674573
  21. ^ a b c Tsai CC, Chen CL, Liu HC, Lee YT, Wang HW, Hou LT, Hung SC (July 2010). "Overexpression of hTERT increases stem-like properties and decreases spontaneous differentiation in human mesenchymal stem cell lines". Journal of Biomedical Science. 17: 64. doi:10.1186/1423-0127-17-64. PMC 2923118. PMID 20670406
  22. ^ a b Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G, et al. (April 2006). "hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis". Cancer Research. 66 (7): 3531–40. doi:10.1158/0008-5472.CAN-05-2183. PMID 16585177
  23. ^ Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, et al. (January 1998). "Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas". Nature Genetics. 18 (1): 65–8. doi:10.1038/ng0198-65. PMID 9425903
  24. ^ a b Elwood NJ, Jiang XR, Chiu CP, Lebkowski JS, Smith CA (March 2004). "Enhanced long-term survival, but no increase in replicative capacity, following retroviral transduction of human cord blood CD34+ cells with human telomerase reverse transcriptase". Haematologica. 89 (3): 377–8. PMID 15020288
  25. ^ McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, et al. (December 2008). "Lung cancer susceptibility locus at 5p15.33". Nature Genetics. 40 (12): 1404–6. doi:10.1038/ng.254. PMC 2748187. PMID 18978790
  26. ^ Baird DM (May 2010). "Variation at the TERT locus and predisposition for cancer". Expert Reviews in Molecular Medicine. 12: e16. doi:10.1017/S146239941000147X. PMID 20478107
  27. ^ a b c d e f g h i j Sundin T, Hentosh P (March 2012). "InTERTesting association between telomerase, mTOR and phytochemicals". Expert Reviews in Molecular Medicine. 14: e8. doi:10.1017/erm.2012.1. PMID 22455872
  28. ^ a b c d Zhang X, Mar V, Zhou W, Harrington L, Robinson MO (September 1999). "Telomere shortening and apoptosis in telomerase-inhibited human tumor cells". Genes & Development. 13 (18): 2388–99. doi:10.1101/gad.13.18.2388. PMC 317024. PMID 10500096
  29. ^ a b c “Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis”. Journal of the National Cancer Institute 104 (11): 840–54. (June 2012). doi:10.1093/jnci/djs222. PMC 3611810. PMID 22523397. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611810/. 
  30. ^ a b c Glukhov AI, Svinareva LV, Severin SE, Shvets VI (2011). "Telomerase inhibitors as novel antitumour drugs". Applied Biochemistry and Microbiology. 47 (7): 655–660. doi:10.1134/S0003683811070039
  31. ^ Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (February 2013). "Highly recurrent TERT promoter mutations in human melanoma". Science. 339 (6122): 957–9. doi:10.1126/science.1229259. PMC 4423787. PMID 23348506
  32. ^ Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M (April 2000). "Cytotoxic T cell immunity against telomerase reverse transcriptase in humans". Proceedings of the National Academy of Sciences of the United States of America. 97 (9): 4796–801. Bibcode:2000PNAS...97.4796M. doi:10.1073/pnas.070560797. PMC 18312. PMID 10759561
  33. ^ “Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors”. Cancer Gene Therapy 10 (3): 239–49. (March 2003). doi:10.1038/sj.cgt.7700563. PMID 12637945. 
  34. ^ “The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes”. Immunity 10 (6): 673–9. (June 1999). doi:10.1016/S1074-7613(00)80066-7. PMID 10403642. 
  35. ^ “A new era for cancer immunotherapy based on the genes that encode cancer antigens”. Immunity 10 (3): 281–7. (March 1999). doi:10.1016/S1074-7613(00)80028-X. PMID 10204484. 
  36. ^ a b c “Induction of pluripotent stem cells from adult human fibroblasts by defined factors”. Cell 131 (5): 861–72. (November 2007). doi:10.1016/j.cell.2007.11.019. hdl:2433/49782. PMID 18035408. 
  37. ^ a b c “Immortalization eliminates a roadblock during cellular reprogramming into iPS cells”. Nature 460 (7259): 1145–8. (August 2009). Bibcode2009Natur.460.1145U. doi:10.1038/nature08285. PMC 3987892. PMID 19668190. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987892/. 
  38. ^ a b c “Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells”. Nature 474 (7351): 399–402. (May 2011). doi:10.1038/nature10084. PMC 3155806. PMID 21602826. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155806/. 
  39. ^ “Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients”. Nature 464 (7286): 292–6. (March 2010). Bibcode2010Natur.464..292A. doi:10.1038/nature08792. PMC 3058620. PMID 20164838. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058620/. 
  40. ^ a b c “Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells”. Blood 114 (11): 2236–43. (September 2009). doi:10.1182/blood-2008-09-178871. PMC 2745844. PMID 19561322. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745844/. 
  41. ^ a b “Linking functional decline of telomeres, mitochondria and stem cells during ageing”. Nature 464 (7288): 520–8. (March 2010). Bibcode2010Natur.464..520S. doi:10.1038/nature08982. PMC 3733214. PMID 20336134. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733214/. 
  42. ^ a b “Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice”. Nature 469 (7328): 102–6. (January 2011). Bibcode2011Natur.469..102J. doi:10.1038/nature09603. PMC 3057569. PMID 21113150. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057569/. 
  43. ^ “Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer”. EMBO Molecular Medicine 4 (8): 691–704. (August 2012). doi:10.1002/emmm.201200245. PMC 3494070. PMID 22585399. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494070/. 
  44. ^ “GWAS of epigenetic aging rates in blood reveals a critical role for TERT”. Nature Communications 9 (1): 387. (January 2018). Bibcode2018NatCo...9..387L. doi:10.1038/s41467-017-02697-5. PMC 5786029. PMID 29374233. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786029/. 
  45. ^ a b c “Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells”. Molecular Therapy 2 (6): 539–44. (December 2000). doi:10.1006/mthe.2000.0196. PMID 11124054. 
  46. ^ a b “[Experimental research of targeting hTERT gene inhibited in hepatocellular carcinoma therapy by RNA interference]” (Chinese). Ai Zheng = Aizheng = Chinese Journal of Cancer 23 (6): 619–25. (June 2004). PMID 15191658. 
  47. ^ “Evaluation of combination gene therapy with PTEN and antisense hTERT for malignant glioma in vitro and xenografts”. Cellular and Molecular Life Sciences 64 (5): 621–31. (March 2007). doi:10.1007/s00018-007-6424-4. PMID 17310280. 
  48. ^ a b “FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo”. Anticancer Research 21 (3B): 1937–43. (2001). PMID 11497281. 
  49. ^ a b “Adenovirus-mediated suicide gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter induced apoptosis of ovarian cancer cell line”. Bioscience, Biotechnology, and Biochemistry 67 (11): 2344–50. (November 2003). doi:10.1271/bbb.67.2344. PMID 14646192. 
  50. ^ “The use of polyethylenimine-DNA to topically deliver hTERT to promote hair growth”. Gene Therapy 19 (1): 86–93. (January 2012). doi:10.1038/gt.2011.62. PMID 21593794. 
  51. ^ “Regulation of telomerase activity and anti-apoptotic function by protein-protein interaction and phosphorylation”. FEBS Letters 536 (1-3): 180–6. (February 2003). doi:10.1016/S0014-5793(03)00058-9. PMID 12586360. 
  52. ^ “IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3'-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells”. Journal of Immunology 174 (9): 5261–9. (May 2005). doi:10.4049/jimmunol.174.9.5261. PMID 15843522. 
  53. ^ a b “Human Ku70/80 associates physically with telomerase through interaction with hTERT”. The Journal of Biological Chemistry 277 (49): 47242–7. (December 2002). doi:10.1074/jbc.M208542200. PMID 12377759. 
  54. ^ “Human MCRS2, a cell-cycle-dependent protein, associates with LPTS/PinX1 and reduces the telomere length”. Biochemical and Biophysical Research Communications 316 (4): 1116–23. (April 2004). doi:10.1016/j.bbrc.2004.02.166. PMID 15044100. 
  55. ^ “Nucleolin interacts with telomerase”. The Journal of Biological Chemistry 279 (49): 51508–15. (December 2004). doi:10.1074/jbc.M407643200. PMID 15371412. 
  56. ^ “The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor”. Cell 107 (3): 347–59. (November 2001). doi:10.1016/S0092-8674(01)00538-4. PMID 11701125. 
  57. ^ “Involvement of 14-3-3 proteins in nuclear localization of telomerase”. The EMBO Journal 19 (11): 2652–61. (June 2000). doi:10.1093/emboj/19.11.2652. PMC 212742. PMID 10835362. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC212742/. 
  58. ^ “PAR-4 and hTERT expression are negatively correlated after RNA interference targeting hTERT in laryngocarcinoma cells”. Tissue & Cell 42 (6): 365–9. (December 2010). doi:10.1016/j.tice.2010.08.002. PMID 20970818. 


「テロメラーゼ逆転写酵素」の続きの解説一覧



英和和英テキスト翻訳>> Weblio翻訳
英語⇒日本語日本語⇒英語
  
  •  テロメラーゼ逆転写酵素のページへのリンク

辞書ショートカット

すべての辞書の索引

「テロメラーゼ逆転写酵素」の関連用語

テロメラーゼ逆転写酵素のお隣キーワード
検索ランキング

   

英語⇒日本語
日本語⇒英語
   



テロメラーゼ逆転写酵素のページの著作権
Weblio 辞書 情報提供元は 参加元一覧 にて確認できます。

   
ウィキペディアウィキペディア
All text is available under the terms of the GNU Free Documentation License.
この記事は、ウィキペディアのテロメラーゼ逆転写酵素 (改訂履歴)の記事を複製、再配布したものにあたり、GNU Free Documentation Licenseというライセンスの下で提供されています。 Weblio辞書に掲載されているウィキペディアの記事も、全てGNU Free Documentation Licenseの元に提供されております。

©2024 GRAS Group, Inc.RSS